This novel interleukin-23 inhibitor targets psoriatic inflammation.
In late-breaking clinical trials, 3 novel biologic drugs show promise for the treatment of moderate to severe plaque psoriasis.
However, the degree to which biosimilars will drive down the cost of biologic therapy remains to be seen.
Mepolizumab gets the nod for the rare disease formerly known as Churg-Strauss syndrome.
The aim of this study: to determine which patients need biologic therapy after starting methotrexate.
Sjogren’s fails a clinical trial with rituximab and a cost analysis. Even with a significant discount, it’s still not cost effective.
The choice of a biologic agent for treating rheumatoid arthritis (RA) may influence a patient’s risk of serious infections.